 CAMBRIDGE, Mass., Nov. 07, 2022 GLOBE NEWSWIRE -- Vigil Neuroscience, Inc. Nasdaq: VIGL, a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at three upcoming investor conferences. Details are as follows: 